A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis.

Trial Profile

A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis D
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 31 Dec 2015 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 31 Dec 2015 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 23 May 2013 Planned end date changed from 1 May 2018 to 1 Nov 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top